Page Title
Drug Development Pipeline
Back to the Drug Development Pipeline
Dornase Alfa (Pulmozyme®)
Status
To PatientsTherapeutic Approach
Mucociliary Clearance
Dornase alfa (Pulmozyme®) is an inhaled medication that thins and loosens mucus in the airways of people with CF.
Status
A Phase 3 clinical trial showed improvement in lung function and reduction in pulmonary exacerbations. It received FDA approval in 1993.
Sponsor
The program was sponsored by Genentech, Inc and the Cystic Fibrosis Foundation.
CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More